386 related articles for article (PubMed ID: 28938491)
21. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
22. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast Growth Factor 2 High Molecular Weight Isoforms in Dentoalveolar Mineralization.
Millington G; Joseph J; Xiao L; Vijaykumar A; Mina M; Hurley MM
Calcif Tissue Int; 2022 Jan; 110(1):93-103. PubMed ID: 34245331
[TBL] [Abstract][Full Text] [Related]
24. Mineralized tissues in hypophosphatemic rickets.
Robinson ME; AlQuorain H; Murshed M; Rauch F
Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
[TBL] [Abstract][Full Text] [Related]
25. Knockout of nuclear high molecular weight FGF2 isoforms in mice modulates bone and phosphate homeostasis.
Homer-Bouthiette C; Doetschman T; Xiao L; Hurley MM
J Biol Chem; 2014 Dec; 289(52):36303-14. PubMed ID: 25389287
[TBL] [Abstract][Full Text] [Related]
26. SPR4-peptide alters bone metabolism of normal and HYP mice.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577
[TBL] [Abstract][Full Text] [Related]
27. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
28. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
29. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
30. Osteocytes and the pathogenesis of hypophosphatemic rickets.
Yamazaki M; Michigami T
Front Endocrinol (Lausanne); 2022; 13():1005189. PubMed ID: 36246908
[TBL] [Abstract][Full Text] [Related]
31. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
32. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.
Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI
Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089
[TBL] [Abstract][Full Text] [Related]
33. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice.
Carpenter KA; Davison R; Shakthivel S; Anderson KD; Ko FC; Ross RD
Bone; 2022 Jan; 154():116201. PubMed ID: 34537437
[TBL] [Abstract][Full Text] [Related]
34. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse.
Brownstein CA; Zhang J; Stillman A; Ellis B; Troiano N; Adams DJ; Gundberg CM; Lifton RP; Carpenter TO
Endocrinology; 2010 Feb; 151(2):492-501. PubMed ID: 19952276
[TBL] [Abstract][Full Text] [Related]
35. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.
Suvannasankha A; Tompkins DR; Edwards DF; Petyaykina KV; Crean CD; Fournier PG; Parker JM; Sandusky GE; Ichikawa S; Imel EA; Chirgwin JM
Oncotarget; 2015 Aug; 6(23):19647-60. PubMed ID: 25944690
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of bone mineral density and microarchitectural parameters by DXA and HR-pQCT in 37 children and adults with X-linked hypophosphatemic rickets.
Colares Neto GP; Pereira RM; Alvarenga JC; Takayama L; Funari MF; Martin RM
Osteoporos Int; 2017 May; 28(5):1685-1692. PubMed ID: 28194480
[TBL] [Abstract][Full Text] [Related]
37. Skeletal inflammation and attenuation of Wnt signaling, Wnt ligand expression, and bone formation in atherosclerotic ApoE-null mice.
Liu Y; Almeida M; Weinstein RS; O'Brien CA; Manolagas SC; Jilka RL
Am J Physiol Endocrinol Metab; 2016 May; 310(9):E762-73. PubMed ID: 26956187
[TBL] [Abstract][Full Text] [Related]
38. Osteoblast-Specific Overexpression of Human WNT16 Increases Both Cortical and Trabecular Bone Mass and Structure in Mice.
Alam I; Alkhouli M; Gerard-O'Riley RL; Wright WB; Acton D; Gray AK; Patel B; Reilly AM; Lim KE; Robling AG; Econs MJ
Endocrinology; 2016 Feb; 157(2):722-36. PubMed ID: 26584014
[TBL] [Abstract][Full Text] [Related]
39. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
40. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development.
Segawa H; Onitsuka A; Furutani J; Kaneko I; Aranami F; Matsumoto N; Tomoe Y; Kuwahata M; Ito M; Matsumoto M; Li M; Amizuka N; Miyamoto K
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F671-8. PubMed ID: 19570882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
